retatrutide fat loss clinical trial results Biggest obesity news 🚨 TRIUMPH-1 are here: Retatrutide's phase 3 showed up to 28% average weight over 80 weeks — with nearly half of patients losing over 30% of Perceived benefits of treatment for

GLP-1 drugs may reduce: Frequency of drinking Volume per occasion Desire to drink What this means across the three-tier system Suppliers Monitor changes in premium product demand Evaluate opportunities in lower-ABV and alternative beverages Distributors Watch for shifts in order frequency and product mix Identify regional differences tied to demographics and health trends Retailers On-premise: fewer drinks per visit Off-premise: smaller baskets and substitution effects Why this is a data problem If youre in beverage alcohol, this is a trend you wont see in your dashboardbut you will see it in your data

1d and Table 1)

Some practitioners recommend using Pendulum GLP-1 Probiotic Pro alongside injectable GLP-1 medications rather than as a replacement

Phase 2 data showed improvements in fasting glucose, HbA1c, insulin sensitivity, triglycerides, waist circumference, and liver fat content measured by MRI

The evidence for split dosing with retatrutide specifically is limited since clinical trials used once-weekly dosing exclusively